Trans American Aquaculture (GRPS) EBITDA Margin (2023 - 2024)
Trans American Aquaculture (GRPS) reported EBITDA Margin of 1193.12% for Q4 2024, down 76728.0% on a YoY basis from N/an in Q1 2024, and up 51.61% quarter-over-quarter from 2465.53% in Q2 2024.
Trans American Aquaculture (GRPS) EBITDA Margin (2023 - 2024) Analysis & Trends
Trans American Aquaculture has reported EBITDA Margin for 2 years, with the latest figure at 1193.12% in Q4 2024.
- For the quarter ending Q4 2024, EBITDA Margin fell 76728.0% year-over-year to 1193.12%; the trailing twelve-month figure through Sep 2025 stood at 2807.41% (down 254329.0% YoY), and the FY2024 full-year result was 252.14%, up 115057.0% from the prior year.
- EBITDA Margin for Q4 2024 stood at 1193.12%, up from 2465.53% in the prior quarter.
- The five-year high for EBITDA Margin was 43.37% in Q1 2024, with the low at 2465.53% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -170.35% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 21.55% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -16.25% |
| 10 | Trans American Aquaculture | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,193.12% |
| Jun 30, 2024 | -2,465.53% |
| Mar 31, 2024 | -43.37% |
| Dec 31, 2023 | -425.84% |